Group 1 - The vaccine sector is experiencing a strong performance, with the medical ETF (159929) gaining 0.43% in the afternoon and surpassing a trading volume of 1.2 billion yuan, exceeding last Friday's total [1][3] - The medical ETF's constituent stocks are mostly in the green, with notable gains in vaccine stocks: Zhifei Biological up over 14%, Watson Bio up over 10%, and Hualan Biological up over 6% [3] - The top ten weighted stocks in the medical ETF account for 42.97% of the index, indicating a concentrated investment in key players within the pharmaceutical sector [7][8] Group 2 - Hualan Biological's subsidiary has received approval for clinical trials of its shingles vaccine, marking a significant breakthrough in its pipeline for preventive medicine, with expectations of increased demand due to an aging population [5] - Yiling Pharmaceutical forecasts a net profit of 1.2 to 1.3 billion yuan for 2025, indicating a turnaround from previous losses and signaling a critical operational inflection point [5] - The development of therapeutic cancer vaccines is entering a breakthrough phase, with mRNA technology leading the shift towards efficient and personalized immunotherapy, offering advantages in production, clinical safety, and strategic flexibility [6]

证券日报网讯1月22日，华兰生物（002007）在互动平台回答投资者提问时表示，截至2026年1月20日， 公司股东共有14.8万余户。 ...

Core Viewpoint - Hualan Biological has received approval from the National Medical Products Administration for a clinical trial of its recombinant herpes zoster vaccine, marking a significant step towards entering the clinical trial phase for this preventive biological product [1] Group 1 - Hualan Biological's subsidiary, Hualan Biological Vaccine Co., Ltd., has been granted a clinical trial approval notice for the herpes zoster vaccine [1] - The vaccine is classified as a preventive biological product of category 1.3, indicating its intended use for the prevention of herpes zoster [1] - This approval allows the company to officially commence clinical trials for the vaccine [1]

Core Viewpoint - Hualan Biological's subsidiary has received approval for a clinical trial of a recombinant shingles vaccine, indicating a significant step in addressing the growing demand for shingles vaccination in China due to an aging population and increased health awareness [1] Company Summary - Hualan Biological's subsidiary, Hualan Biological Vaccine Co., Ltd., has been granted a Clinical Trial Approval Notice by the National Medical Products Administration for its recombinant shingles vaccine [1] - The vaccine utilizes a mature CHO cell platform to express key proteins of the varicella-zoster virus, aiming to induce immune responses to prevent shingles and its complications [1] - This product represents an important strategic move for Hualan in the shingles prevention sector, potentially offering a new preventive option for susceptible populations [1] Industry Summary - Shingles is caused by the reactivation of the varicella-zoster virus, primarily affecting middle-aged and elderly individuals, with symptoms worsening with age [1] - Currently, there are two marketed shingles vaccines in China, indicating a competitive landscape [1] - The demand for shingles vaccination is expected to grow significantly due to the accelerating aging process in the country and rising public health awareness, suggesting a promising market outlook for domestic shingles vaccines [1]

近日，华兰生物工程股份有限公司（以下简称"公司"）控股子公司华兰生 物疫苗股份有限公司（以下称"华兰疫苗"）收到国家药品监督管理局下发的《药 物临床试验批准通知书》（通知书编号：2026LP00175）。现将相关情况公告如 下： 一、药物基本情况 证券代码：002007 证券简称：华兰生物 公告编号：2026-002 华兰生物工程股份有限公司 关于控股子公司收到药物临床试验批准通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 截至本公告披露日，经查询国家药品监督管理局官网，国内已上市的带状疱 疹疫苗产品有两款，分别是智飞生物代理的葛兰素史克（GSK）重组带状疱疹疫 苗和百克生物减毒活带状疱疹疫苗。随着国内老龄化进程加快以及公众健康意识 提升，带状疱疹疫苗接种需求仍有较大的增长空间，未来国产带状疱疹疫苗的市 场发展前景较为广阔。 华兰疫苗研发的重组带状疱疹疫苗（CHO 细胞）利用成熟的 CHO 细胞平台表 达水痘-带状疱疹病毒关键蛋白，通过诱导免疫应答预防带状疱疹及其并发症。 该产品是华兰疫苗在带状疱疹预防领域的重要布局，有望为易感人群提供新的预 防 ...

Core Viewpoint - Hualan Biological (002007.SZ) announced that its subsidiary Hualan Vaccine (301207) received approval from the National Medical Products Administration for clinical trials of a recombinant shingles vaccine, marking a significant step in the company's strategy for shingles prevention [1] Company Summary - Hualan Vaccine's recombinant shingles vaccine is designed to prevent shingles, but not primary varicella [1] - This vaccine represents an important development in Hualan Vaccine's portfolio within the shingles prevention market [1] Industry Summary - Currently, there are two shingles vaccine products available in the domestic market, indicating existing competition [1] - The aging population and increasing public health awareness are expected to drive significant market growth for shingles vaccines [1] - Vaccine development cycles are lengthy, and future progress and outcomes remain uncertain [1]

Core Viewpoint - The company, Hualan Biological Engineering, announced that its subsidiary, Hualan Vaccine, has received approval from the National Medical Products Administration for clinical trials of a recombinant herpes zoster vaccine [1] Group 1: Product Details - The drug is classified as a Class 1.3 preventive biological product and is intended for the prevention of herpes zoster, not for the prevention of primary varicella [1] - The approval indicates that the vaccine meets the necessary requirements for drug registration and is recommended for clinical trial initiation [1]

Core Viewpoint - The company Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Ankang Biological Co., Ltd., has received a notice of acceptance for the application for the production registration of Adalimumab injection from the National Medical Products Administration of China [1] Group 1: Company Developments - Hualan Ankang is developing Adalimumab injection as a biosimilar drug [1] - The original product was developed by AbbVie and has been approved for marketing in multiple countries and regions worldwide [1] - Adalimumab is used to treat various immune diseases, including rheumatoid arthritis, ankylosing spondylitis, and psoriasis, with its efficacy and safety widely validated in clinical settings [1]

证券代码：002007 证券简称：华兰生物 公告编号：2026-001 华兰生物工程股份有限公司 关于参股公司收到药品注册受理通知书的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没 有虚假记载、误导性陈述或重大遗漏。 近日，华兰生物工程股份有限公司（以下简称"公司"）参股公司华兰安康 生物股份有限公司（原名：华兰基因工程有限公司，以下简称"华兰安康"）收 到国家药品监督管理局签发的阿达木单抗注射液境内生产药品注册上市许可申 请《受理通知书》（受理号：CXSS2600006）。现将相关情况公告如下： 一、申请注册药品的基本情况 药 品 名 称 ：阿达木单抗注射液 申 请 事 项 ：境内生产药品注册上市许可 相互作用，从而有效抑制炎症反应、减轻组织破坏、改善临床症状，是临床重要 的免疫性疾病治疗药物。 经查询国家药监局网站显示，截至本公告披露日，国内已有神州细胞工程有 限公司等 8 家公司的阿达木单抗注射液获批上市，若华兰安康该产品最终获批上 市，将丰富其产品梯队，为其增加新的利润增长点。 三、对公司的影响及风险提示 根据国家相关法规规定，上述阿达木单抗注射液已获得注册上市申请受理， 报送国家 ...

Core Viewpoint - The company Hualan Biological (002007.SZ) announced that its subsidiary, Hualan Ankang, received a notice of acceptance for the production registration application of Adalimumab injection from the National Medical Products Administration, indicating progress in the development of a biosimilar drug for various immune diseases [1] Group 1 - The drug Adalimumab is intended for the treatment of rheumatoid arthritis, ankylosing spondylitis, psoriasis, and other immune-related diseases [1] - As of the announcement date, eight other companies in China have already received approval for their Adalimumab injections [1] - The acceptance notice for the drug will not impact the company's recent performance, as the timing and outcome of the registration approval remain uncertain [1]